The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’

Braveheart Bio (Nasdaq: BRVE) completed its IPO, raising $122.8 million. The proceeds will fund its lead drug candidate, BHB-1893, for hypertrophic cardiomyopathy. The company reported Q2 2026 R&D expenses of $11.1 million and a net loss of $18.6 million. Cash reserves increased to $122.8 million as of June 30, 2026.

Braveheart Bio, Inc. (BRVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After G

Latigo Biotherapeutics (LTGO) reported Q2 2026 results, raising $397.4M in an upsized IPO. Cash reserves reached $55.0M pre-IPO. R&D expenses were $21.2M, G&A $4.6M, with a net loss of $25.8M. The company reported positive clinical trial results for onzotrigine and plans Phase 3 trials. It also initiated a Phase 2 trial for LTG-321.

Latigo Biotherapeutics (LTGO) reported a narrower Q2 loss of $(27.59) per share, a 24% improvement YoY, with no sales. The company plans to raise $256M-$288M via an IPO, offering 16M shares at $16-$18 each, listing on Nasdaq.

Latigo Biotherapeutics reported a net loss of $25.8M for 2Q 2026, matching the prior-year quarter, with a diluted net loss per share of $27.59. The company remains pre-revenue. Clinical trials for onzotrigine met key endpoints, and new trials are planned. The company expects cash runway into 2029.

Latigo Biotherapeutics reported positive pivotal trial results for onzotrigine in treating acute pain, with Phase 3 trials and data expected in 2027. The company raised $363.9M in an IPO, funding operations into 2029, but anticipates needing more capital for full development and commercialization. Risks include ongoing losses and regulatory challenges.